Latest News
BrightFocus Foundation today announced that its 2015 research program grants have been awarded to 58 scientists in 20 states and 7 foreign countries. Part of an $11 million research investment, the grants reflect the largest annual research funding in the foundation’s history.
Download the summer edition of our Alzheimer's disease newsletter and learn about a cancer drug that shows early promise as an Alzheimer's treatment, a new drug that passes early clinical trial tests in humans, and other helpful information.
Download the summer 2015 issue of our macular degeneration newsletter to learn about a new AMD treatment that is close to human clinical trials, how cataract surgery affects AMD, AREDS vitamins. risk reduction strategies for AMD, and more.
Two BrightFocus grantees are honored by receiving the 2015 MetLife Foundation Awards in Medical Research, which work to stimulate novel investigations in the field of Alzheimer’s disease.
Scott Rodgville, a prominent Baltimore area CPA, has been elected chair of the Board of Directors of the BrightFocus Foundation, a Maryland non-profit supporting innovative research worldwide on Alzheimer’s, macular degeneration, and glaucoma.
Download the summer 2015 issue of our glaucoma newsletter to learn about how a healthy diet leads to healthy eyes, how to make your computer vision-friendly, and much more.
BrightFocus Foundation seeks to save sight and mind by funding innovative research worldwide and by promoting better health through education.
In an online report published April 2, 2014, BrightFocus researchers Matthew Campbell, PhD, Sarah Doyle, PhD, and Peter Humphries, PhD, and their teams, have reported from studies in mice that the inflammatory cytokine interleukin-18 (IL-18) can prevent choroidal neovascularization (CNV) formation—the fragile, leaky blood vessels forming on the retina that are the hallmark of wet AMD—and is not toxic to the retinal pigment epithelium.
